Catalyst Pharmaceuticals, Inc.
CPRX
$21.02
$0.150.72%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 10.20% | 4.88% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 10.20% | 4.88% | |||
| Cost of Revenue | -35.41% | 22.68% | |||
| Gross Profit | 19.89% | 1.74% | |||
| SG&A Expenses | -3.68% | 12.64% | |||
| Depreciation & Amortization | -0.01% | 0.01% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.53% | 13.62% | |||
| Operating Income | 23.44% | -6.15% | |||
| Income Before Tax | 29.68% | 2.54% | |||
| Income Tax Expenses | 36.96% | -11.16% | |||
| Earnings from Continuing Operations | 27.46% | 7.57% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 27.46% | 7.57% | |||
| EBIT | 23.44% | -6.15% | |||
| EBITDA | 19.78% | -5.22% | |||
| EPS Basic | 26.45% | 6.89% | |||
| Normalized Basic EPS | 20.69% | -5.08% | |||
| EPS Diluted | 25.23% | 6.06% | |||
| Normalized Diluted EPS | 20.85% | -5.08% | |||
| Average Basic Shares Outstanding | 0.81% | 0.64% | |||
| Average Diluted Shares Outstanding | 0.70% | 0.60% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
